Aldoss I et al. Updated results and longer follow-up from the AUGMENT-101 phase 2 study of revumenib in patients with relapsed or refractory (R/R) KMT2Ar acute leukemia. EHA 2025;Abstract PS1473.
Arellano ML et al. Patients with relapsed or refractory R/R) nucleophosmin 1-mutated (NPM1m) acute myeloid leukemia (AML): Updated results from the phase 2 AUGMENT-101 study. EHA 2025;Abstract PS1467.
Daver N et al. Monotherapy update from phase 1 portion in phase1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia. ASH 2025;Abstract 763.
Döhner H et al. Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed acute myeloid leukemia with KMT2A or NPM1 alterations. ASH 2025;Abstract 5199.
Erba H et al. Ziftomenib combined with intensive induction chemotherapy (7+3) in newly diagnosed NPM1-M or KMT2A-R acute myeloid leukemia (AML): Updated phase 1a/b results from KOMET-007. EHA 2025;Abstract S136.
Fathi A et al. Results from paradigm — A phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia. ASH 2025;Abstract 6.
Huether R et al. Detection of KMT2A partial tandem duplication (PTD) in AML by whole genome sequencing (WGS): Addressing limitations of traditional techniques in the era of revumenib approval. ASCO 2025;Abstract 6532.
Issa G et al. Revumenib activity in patients with acute leukemia with NUP98r: Results from the AUGMENT-101 phase 1 study. EHA 2025;Abstract PS1501.
Issa G et al. Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007. ASH 2025;Abstract 764.
Issa GC et al. Combination strategies with menin inhibitors for acute leukemia. Blood Cancer Discov 2025;6(6):547-560. Abstract
Jen W-Y et al. Phase II study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML. ASH 2025;Abstract 47.
Roboz G et al. Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007. ASH 2025;Abstract 766.
Shukla N et al. Detection of MEN1 resistance mutations in cell-free DNA from acute leukemia patients treated with menin inhibitors. ASH 2025;Abstract 938.
Veiga RR et al. Real world outcomes in a series of 417 adult patients with KMT2A (MLL) gene rearranged acute myeloid leukemia. EHA 2025;Abstract S147.
Wang ES at al. Ziftomenib in relapsed or refractory NPM1-mutated AML. J Clin Oncol 2025;43(31):3381-90. Abstract
Watts J et al. Preliminary data from the ongoing phase 1 study of the menin-MLL inhibitor enzomenib (DSP-5336) in combination with venetoclax and azacitidine in patients with relapsed or refractory acute myeloid leukemia. ASH 2025;Abstract 765.
Wei AH et al. RP2D determination of bleximenib in combination with VEN + AZA: Phase 1b study in ND & R/R AML with KMT2A/NPM1 alterations. EHA 2025;Abstract S137.
Zeidner JF et al. Azacitidine, venetoclax, and revumenib for newly diagnosed NPM1-mutated or KMT2A-rearranged AML. J Clin Oncol 2025;43(23):2606-15. Abstract